ETHIOPIAN INTERNATIONAL JOURNAL OF MULTIDISCIPLINARY RESEARCH

eISSN: 2349-5715 pISSN: 2349-5707

Volume: 12, Issue 02, February-2025 SJIF 2019: 4.702 2020: 4.737 2021: 5.071 2022: 4.919 2023: 6.980 2024: 7,662

Oripova Jamila Nematovna

Department of Infectious diseases,

Andijan State Medical Institute,

Andijan, Uzbekistan

THE USE OF HEPATOPROTECTORS IN THE TREATMENT OF VIRAL HEPATITIS B

Abstract: Viral hepatitis B remains a significant global health concern, affecting over 250 million people worldwide. Although antiviral therapy—particularly nucleos(t)ide analogs or interferon-based regimens—represents the primary means of controlling Hepatitis B virus (HBV) replication, hepatoprotectors have been increasingly used as adjuncts to protect and enhance liver function. This article reviews the rationale for using hepatoprotectors, discusses their potential benefits and limitations, and explores future directions in integrating hepatoprotectors into comprehensive therapy for chronic hepatitis B (CHB) patients.

Keywords:hepatitis B, hepatoprotectors, liver, chronic hepatitis, antiviral therapy, liver protection

Introduction

Chronic hepatitis B (CHB) infection is a life-threatening disease that can lead to cirrhosis, hepatic decompensation, and hepatocellular carcinoma (HCC). Advances in antiviral therapy (e.g., tenofovir, entecavir) have significantly reduced HBV replication and improved long-term outcomes 111. However, persistent inflammatory liver damage can still occur, particularly in patients with advanced fibrosis or underlying comorbidities [1].

Hepatoprotectors—agents purported to support, protect, or enhance liver cell function—are frequently used in many regions worldwide to supplement standard CHB therapy 222. This article examines the proposed mechanisms of action of various hepatoprotectors, their clinical evidence base in hepatitis B, and the arguments for integrating them into treatment regimens alongside direct-acting antiviral agents [2].

Overview of Hepatoprotectors

Rationale for Use

Hepatoprotectors aim to:

Stabilize Hepatocyte Membranes: Reducing oxidative and immunologic damage to liver cells.

Improve Bile Flow: Certain agents (e.g., ursodeoxycholic acid) can modulate bile composition and potentially alleviate cholestasis.

Boost Antioxidant Defense: Enhancing the liver's capacity to neutralize free radicals that exacerbate hepatic injury.

While they do not directly inhibit HBV replication, hepatoprotectors may minimize the hepatic necroinflammatory response and slow fibrosis progression.

Common Classes of Hepatoprotectors

eISSN: 2349-5715 pISSN: 2349-5707

Volume: 12, Issue 02, February-2025 SJIF 2019: 4.702 2020: 4.737 2021: 5.071 2022: 4.919 2023: 6.980 2024: 7,662

Essential Phospholipids (e.g., phosphatidylcholine): Thought to restore membrane integrity in damaged hepatocytes.

Silymarin (Milk Thistle Extract): Contains silybin, silydianin, and silychristin, which possess antioxidant and anti-inflammatory properties.

Ursodeoxycholic Acid (UDCA): Used primarily for cholestatic liver diseases, but also considered in some cases of CHB with cholestatic features.

Amino Acids and Derivatives (e.g., L-ornithine L-aspartate): May improve ammonia detoxification and reduce hepatic encephalopathy risk.

Antioxidant Vitamins and Supplements (e.g., vitamin E, vitamin C, beta-carotene): Proposed to limit oxidative damage.

Clinical Evidence in Chronic Hepatitis B

Essential Phospholipids

Essential phospholipids have been widely studied in non-alcoholic fatty liver disease (NAFLD) and alcoholic liver disease, but their efficacy in chronic hepatitis B is less definitive 333. Some open-label studies suggest improvement in transaminase levels and histological scores, but randomized controlled trials (RCTs) are limited and often show mixed results [3].

Silymarin

Silymarin is among the most commonly used herbal hepatoprotectors [4]. Its mechanisms include free-radical scavenging, immunomodulation, and anti-fibrotic activity 444. Preliminary data in CHB patients indicate modest reductions in alanine aminotransferase (ALT) levels, but evidence of reduced progression to cirrhosis is inconclusive. Large-scale, high-quality RCTs in hepatitis B remain sparse [5].

Ursodeoxycholic Acid (UDCA)

UDCA is well-established for primary biliary cholangitis and certain cholestatic conditions. In CHB, UDCA may improve serum liver enzyme levels, but major impacts on long-term clinical outcomes such as cirrhosis or HCC have not been robustly demonstrated [6]. Some clinicians consider UDCA in patients with concomitant cholestatic features or overlapping diseases (e.g., steatohepatitis).

Other Agents

L-ornithine L-aspartate: May help reduce hyperammonemia, particularly in patients with subclinical hepatic encephalopathy.

Antioxidant vitamins: Their benefit in CHB is mainly theoretical or extrapolated from other chronic liver diseases. Well-controlled trials are limited.

Integrating Hepatoprotectors into Antiviral Therapy

Patient Selection

Active Chronic Hepatitis: Patients with persistent elevation of ALT/AST and inflammatory activity might benefit from adjunctive liver support.

F3-F4 Fibrosis (Advanced): Hepatoprotectors may support synthetic function and reduce oxidative stress, although the primary therapy remains potent antiviral agents.

eISSN: 2349-5715 pISSN: 2349-5707

Volume: 12, Issue 02, February-2025 SJIF 2019: 4.702 2020: 4.737 2021: 5.071 2022: 4.919 2023: 6.980 2024: 7,662

Minimal Hepatic Reserve: In decompensated cirrhosis, careful selection and monitoring are essential due to compromised drug metabolism and risk of adverse effects.

Timing and Duration

Optimal duration for hepatoprotector use in CHB is not well-established. Some experts recommend short-term courses (3–6 months) during active flares or in combination with antiviral initiation [7]. Others propose prolonged use in advanced fibrosis if there is evidence of clinical improvement or stable disease.

Monitoring and Outcomes

Biochemical Response: Periodic ALT, AST, GGT, and bilirubin measurements can gauge hepatoprotective effects.

Fibrosis Assessment: Noninvasive markers (FibroScan, serum fibrosis markers) or histology can help track disease progression.

Quality of Life: Improvement in fatigue and overall well-being may be relevant endpoints, in addition to standard biochemical or virological parameters.

Challenges and Future Directions

Despite widespread use, scientific data on the long-term efficacy of hepatoprotectors in CHB are inconsistent [8]. Methodological limitations—small sample sizes, lack of placebo control, and short follow-up durations—hinder definitive conclusions. More rigorous RCTs evaluating clinical outcomes like reduction in fibrosis, decompensation events, and HCC incidence are needed.

Additionally, novel hepatoprotective agents (e.g., statins, mesenchymal stem cell therapies) show promise in experimental models and require further investigation in the context of HBV 555. Combining these agents with potent nucleos(t)ide analogs or immunomodulators might offer synergistic benefits in complex cases.

6. Conclusion

Hepatoprotectors are frequently prescribed as an adjunct to standard antiviral therapy in chronic hepatitis B, aiming to protect hepatocytes and preserve liver function. While they do not directly combat HBV replication, some clinical and experimental data suggest these agents can mitigate oxidative stress, inflammation, and possibly slow fibrosis progression. However, their definitive benefits remain unproven in large-scale, high-quality trials. Clinicians should balance potential advantages against cost and patient tolerance, emphasizing the role of potent antiviral agents as the cornerstone of CHB management. Future research must clarify which patient subgroups and hepatoprotective agents can yield the most meaningful clinical impact.

References:

1. World Health Organization. Global Hepatitis Report 2017. https://www.who.int.
2. Yuldashevich, Oripov Shavkatjon. "THE USE OF NATURAL REMEDIES IN THE COMPLEX TREATMENT AND REHABILITATION OF CHILDREN AFTER ACUTE RESPIRATORY VIRAL INFECTION." International Multidisciplinary Journal for Research & Development 11, no. 01 (2024).

eISSN: 2349-5715 pISSN: 2349-5707

Volume: 12, Issue 02, February-2025 SJIF 2019: 4.702 2020: 4.737 2021: 5.071 2022: 4.919 2023: 6.980 2024: 7,662

3. Nabijonovich, Kaxarov Abdukaxar. "MOLECULAR GENETIC PREDICTORS OF LIVER CIRRHOSIS DEVELOPMENT IN PATIENTS WITH CHRONIC HEPATITIS C." Ethiopian International Journal of Multidisciplinary Research 12, no. 02 (2025): 177-180.
4. Nabijonovich, Kaxarov Abdukaxar. "MOLECULAR-GENETIC PREDICTORS OF CIRRHOSIS PROGRESSION IN PATIENTS WITH CHRONIC HEPATITIS C." Ethiopian International Journal of Multidisciplinary Research 12, no. 02 (2025): 181-186.
5. Gulamovich, Djurayev Muzaffar, and Kaxarov Abdukaxar Nabijonovich. "CHANGES IN THE FUNCTIONAL STATE OF THE THYROID GLAND IN CHILDREN WITH BRONCHIAL ASTHMA." International Multidisciplinary Journal for Research & Development 11, no. 01 (2024).
6. Bakhodirovna, Mirzakarimova Dildora, and Abdukodirov Sherzodjon Taxirovich. "CHARACTERISTICS OF RHINOVIRUS INFECTION." International journal of medical sciences 4, no. 08 (2024): 55-59.
7. Sayibovna, Tuxtanazarova Nargiza. "CURRENT COURSE AND TREATMENT OF CHICKENPOX IN CHILDREN." International Multidisciplinary Journal for Research & Development 11, no. 01 (2024).
8. Sayibovna, Tuxtanazarova Nargiza. "METHODS USED AGAINST SORE THROAT." International Multidisciplinary Journal for Research & Development 11, no. 04 (2024).
9. Bae S, Kim T, et al. Emerging molecular targets and therapeutics for liver fibrosis in chronic hepatitis B. Hepatology. 2021;74(1):345–358.